Business Wire

On the Path to Net Zero: TIWAG Subsidiary TINEXT to Supply INNIO’s Primary Operations in Jenbach with Green Hydrogen

22.9.2022 15:00:00 EEST | Business Wire | Press release

Share

INNIO and TIWAG today announce that TINEXT, a TIWAG (Tiroler Wasserkraft AG) subsidiary, will supply INNIO’s primary operations in Jenbach with green hydrogen (H2) by 2025. At the same time, excess power and heat will be fed into the local power grid and district heating network. Once sufficient quantities of green hydrogen are available, additional areas of application are planned, such as supplying an INNIO plant gas station or refueling local logistics companies’ vehicles.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220922005259/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Vice president and site manager of INNIO's Jenbacher site Martin Mühlbacher, TIWAG managing director Dipl.-Ing Thomas Gasser, and INNIO president and CEO Dr. Olaf Berlien. (Photo: Business Wire)

As part of the joint project, INNIO will install an electrolysis unit on the premises of TIWAG’s Achensee power plant that will convert green electricity into green hydrogen. In turn, TINEXT will construct the compression and storage terminals. The hydrogen, a key component in the energy transition, will be transported via pipeline from TINEXT to INNIO’s main operations in Jenbach, where it will primarily be used for hydrogen engine test runs.

“The hydrogen agreement with TIWAG and TINEXT is another milestone on our path to net zero at our site in Jenbach,” said Olaf Berlien, president and CEO of INNIO. “We have committed to reducing emissions from our production sites around the world by up to 50% by 2030. The products of the future are being developed here in our INNIO360 Energy Lab, where we demonstrate how the energy transition works.”

“Using green hydrogen to generate power is an important step on INNIO’s journey to significantly reduce the carbon footprint of the site in Jenbach,” said Martin Mühlbacher, vice president and site manager in Jenbach. “Along with the use of a photovoltaic system, hydropower plant, battery storage, storage water heater (power-to-heat), and electromobility, this will make an important contribution to implementing our broad-ranging sustainability strategy.”

“This pioneering hydrogen project is a central element of Tyrol’s energy strategy of phasing out the use of fossil fuels. With this agreement, INNIO and TIWAG are showing how the transition to an energy-autonomous and climate-neutral energy supply for industrial companies can be realized,” commented TIWAG managing director Dipl.-Ing Thomas Gasser. “TIWAG has been using hydropower to generate green electricity in Jenbach for almost 100 years. As of this summer, this is supported by a large photovoltaic system. It is all the more gratifying that our subsidiary TINEXT is now suppling green hydrogen for our customer and partner INNIO at this location, which has a long tradition in power generation.”

The availability of green hydrogen is an important prerequisite for the sustainable, economic, and timely implementation of INNIO’s hydrogen strategy. The company began offering all new Jenbacher engines with a “Ready for H2” option this year.

About TIWAG

TIWAG, the state energy utility owned by the State of Tyrol, is tasked with providing a secure, sustainable, and integrated energy supply for Tyrol. The TIWAG Group supports the European and national energy goals and is a driving force behind the ecological transition in Tyrol’s power, gas, and heat supply. TINEXT – TIWAG Next Energy Solutions GmbH, the 100% subsidiary established in 2021, supports the energy transition in the fields of hydrogen, photovoltaics, renewable heat, and electromobility.

About INNIO

INNIO is a leading energy solution and service provider that empowers industries and communities to make sustainable energy work today. With our product brands Jenbacher and Waukesha and our digital platform myPlant, INNIO offers innovative solutions for the power generation and compression segments that help industries and communities generate and manage energy sustainably while navigating the fast-changing landscape of traditional and green energy sources. We are individual in scope, but global in scale. With our flexible, scalable, and resilient energy solutions and services, we are enabling our customers to manage the energy transition along the energy value chain wherever they are in their transition journey.

INNIO is headquartered in Jenbach (Austria), with other primary operations in Waukesha (Wisconsin, U.S.) and Welland (Ontario, Canada). A team of more than 3,500 experts provides life-cycle support to the more than 54,000 delivered engines globally through a service network in more than 80 countries.

INNIO’s ESG Risk Rating places it number one of more than 500 worldwide companies in the machinery industry assessed by Sustainalytics.

For more information, visit INNIO’s website at www.innio.com. Follow INNIO on Twitter and LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Susanne Reichelt
INNIO, Media Relations
+43 664 80833 2382
susanne.reichelt@innio.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release

Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye